Direct observation (DO) for drug-resistant tuberculosis: do we really DO?

Directly-observed therapy (DOT) is recommended for drug-resistant tuberculosis (DR-TB) patients during entire treatment period

From:
Foreign, Commonwealth & Development Office
Published
2 November 2017
Country:
India
Document Type:
Research Paper
Theme:
Health
First published:
1 May 2015
Authors:
Benbaba, S, Isaakidis, P, Das, M, Jadhav, S, Reid, T and Furin, J

Abstract

This cross-sectional, mixed-methods study used existing qualitative data from a purposively-selected subset of 12 patients, 5 DOT-providers and 5 family members, were assessed in order to determine how DO was implemented. A questionnaire-based survey of DR-TB patients, their DOT-providers and MSF staff was completed between June and August 2014. Patients were defined as鈥漟ollowing Strict DO鈥� and 鈥渇ollowing DO鈥� if a DOT-provider had seen the patient swallow his/her medications 鈥渆very day鈥� or 鈥渕ost of the days鈥� respectively. If DO was not followed, reasons were also recorded.

This research was supported by the UK Department for International Development鈥檚 Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Benbaba S, Isaakidis P, Das M, Jadhav S, Reid T, Furin J (2015) Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO? PLoS ONE 10(12): e0144936.

Updates to this page

Published 2 November 2017
Contents